HERCEPTIN® (trastuzumab) subcutaneous (SC) formulation approved in Canada for the treatment of HER2-positive breast cancer

Thursday, September 13, 2018 Women Health News
Email Print This Page Comment bookmark
Font : A-A+

_____________________________

1 HERCEPTIN SC (trastuzumab injection) Product Monograph. Hoffmann-La Roche Limited. September 11, 2018.

2 Slamon D et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. N Engl J Med 2011; 365:1273-83. 

3 Pivot, Semiglazov et al. Subcutaneous injection of trastuzumab – analysis of administration time and injection site reactions. 

4 De Cock, Pivot et al. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer. Cancer Medicine 2016; 5(3):389–397.

5 Ismael, Hegg et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 2012; 13: 869–78. 

6 De Cock, Pivot et al. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer. Cancer Medicine 2016; 5(3):389–397. 

7 De Cock, Pivot et al. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer. Cancer Medicine 2016; 5(3):389–397. 

8 Canadian Cancer Society. Breast Cancer Statistics. http://www.cancer.ca/en/cancer-information/cancer-type/breast/statistics/?region=on. Accessed on June 6, 2018.

9 X. Zhu, MD and S. Verma, MD MSEd. Targeted therapy in her2-positive metastatic breast cancer: a review of the literature. Curr Oncol. 2015 Mar; 22:(Suppl 1): S19–S28. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381788/pdf/conc-22-s19.pdf. 

10 Ismael, Hegg et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 2012; 13: 869–78.

11 Ismael, Hegg et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 2012; 13: 869–78.

12 HERCEPTIN SC (trastuzumab injection) Product Monograph. Hoffmann-La Roche Limited. September 11, 2018. 

13 HERCEPTIN SC (trastuzumab injection) Product Monograph. Hoffmann-La Roche. September 11, 2018.

14 HERCEPTIN SC (trastuzumab injection) Product Monograph. Hoffmann-La Roche Limited. September 11, 2018. 

15 Pan S, Zhu L, Chen M, Xia P, Zhou Q. Weight-based dosing in medication use: what should we know? Patient preference and adherence. 2016;10:549-560. 

16 HERCEPTIN SC (trastuzumab injection) Product Monograph. Hoffmann-La Roche Limited. September 11, 2018. 

17 Pivot, Semiglazov et al. Subcutaneous injection of trastuzumab – analysis of administration time and injection site reactions.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store